Variation in care for recurrent nonmelanoma skin cancer in a university-based practice and a veterans affairs clinic.

Clark FL, Sahay A, Bertenthal D, Maddock L, Lindquist K, Grekin R, Chren MM. Variation in care for recurrent nonmelanoma skin cancer in a university-based practice and a veterans affairs clinic. Archives of dermatology. 2008 Sep 1; 144(9):1148-52.

Related HSR&D Project(s)

• IIR 97-010 – Comprehensive Outcomes of Nonmelanoma Skin Cancer

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

OBJECTIVE: To learn if treatment of recurrent nonmelanoma skin cancer (NMSC) varied in different practice settings. DESIGN: Prospective cohort study of consecutive patients with recurrent NMSC. SETTING: A university-based dermatology practice and the dermatology clinic at the affiliated Veterans Affairs Medical Center (VAMC). Conventional therapies for NMSC were available at both sites. Patients All 191 patients diagnosed as having recurrent NMSC in 1999 and 2000 were included in the study. Data were collected from medical record review and surveys mailed to patients. Main Outcome Measure Performance of Mohs micrographic surgery (Mohs). RESULTS: Patients at the VAMC were older, less educated, poorer, and had more comorbid illnesses, but their tumors were similar to those of patients at the university-based practice. Treatment choices differed at the 2 sites: the proportions of tumors treated in the VAMC and university sites were 60% and 14%, respectively, for excisional surgery; and 24% and 61%, respectively, for Mohs (P < .001). In multivariate analyses adjusting for patient, tumor, and physician features that may have affected treatment choice, tumors treated at the university-based site remained significantly more likely to be treated with Mohs (odds ratio, 8.68 [95% confidence interval, 3.66-20.55]; P < .001). CONCLUSIONS: Substantial variation existed in the treatment of recurrent NMSC in different practice settings. This variation was not explained by measured clinical characteristics of the patients or the tumors.